Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab (Vectibix) plus liposomal doxorubicin (Caelyx) in platinum-resistant ovarian cancer without KRAS mutation
2008-007799-13Phase 2Completed
- Sponsor
- Vejle Hospital
- Start
- Jan 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panitumumab and pegylated liposomal doxorubicin in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Vejle Hospital. Primary endpoint: Objective response rate by GCIG modified CA-125 criteria. Started Jan 2009; status: completed.
02
Drugs
panitumumabpegylated liposomal doxorubicin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2008-007799-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007799-13.